晚期肾细胞癌-话题@MedSci

#晚期肾细胞癌#

45篇内容 | 1157人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1441739, encodeId=3c721441e391f, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=ANN ONCOL：CRLX101联合贝伐单抗与标准疗法比较治疗晚期肾细胞癌, objectType=article, longId=121165, objectId=9a2a12116540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a2a12116540, replyNumber=0, likeNumber=33, createdTime=2017-11-25, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a2a12116540, moduleTitle=ANN ONCOL：CRLX101联合贝伐单抗与标准疗法比较治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a2a12116540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441738, encodeId=eaa41441e3885, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Eur Urol：纳武单抗治疗晚期肾细胞癌的成本效益。, objectType=article, longId=109195, objectId=866d10919523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=866d10919523, replyNumber=0, likeNumber=49, createdTime=2017-08-20, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=866d10919523, moduleTitle=Eur Urol：纳武单抗治疗晚期肾细胞癌的成本效益。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=866d10919523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441737, encodeId=17f31441e37ad, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, objectType=article, longId=79539, objectId=ef32e9539e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef32e9539e8, replyNumber=0, likeNumber=22, createdTime=2016-10-10, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef32e9539e8, moduleTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef32e9539e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441736, encodeId=b3da1441e36a1, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=NEJM：Nivolumab治疗晚期肾细胞癌优于依维莫司（CheckMate 025研究）, objectType=article, longId=57739, objectId=78cc5e739d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78cc5e739d9, replyNumber=0, likeNumber=32, createdTime=2015-10-26, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78cc5e739d9, moduleTitle=NEJM：Nivolumab治疗晚期肾细胞癌优于依维莫司（CheckMate 025研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78cc5e739d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441735, encodeId=c8251441e3504, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=“阿昔替尼”较索拉非尼更能显著延长晚期肾细胞癌患者生存, objectType=article, longId=3535, objectId=93a93535bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a93535bd, replyNumber=0, likeNumber=49, createdTime=2011-12-20, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a93535bd, moduleTitle=“阿昔替尼”较索拉非尼更能显著延长晚期肾细胞癌患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a93535bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期肾细胞癌

2020-05-29

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

ANN ONCOL：CRLX101联合贝伐单抗与标准疗法比较治疗晚期肾细胞癌

2017-11-25

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Eur Urol：纳武单抗治疗晚期肾细胞癌的成本效益。

2017-08-20

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发

2016-10-10

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

NEJM：Nivolumab治疗晚期肾细胞癌优于依维莫司（CheckMate 025研究）

2015-10-26

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

“阿昔替尼”较索拉非尼更能显著延长晚期肾细胞癌患者生存

2011-12-20

科室
- - 订阅+
  - 更多科室
工具
服务